DYRK1B kinase a short while ago emerged as a potential target in cancer, metabolic syndrome, and nonalcoholic fatty liver illness, but The shortage of structural info hinders the design of selective DYRK1B inhibitors. In this article, we offer a way for recombinant production, action assays, crystallization situations as well as a high resolution c